Brought to you by 
Nastech gets nasal patent rights from Thiakis
30 Jun 2005
Executive Summary
Nasal drug delivery company Nastech Pharmaceutical has acquired rights from UK start-up Thiakis Ltd. (therapeutics for metabolic diseases) to a set of patents for the intranasal delivery of peptide YY 3-36 to treat obesity and other metabolic disorders.
Deal Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Nasal
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nastech gets nasal patent rights from Thiakis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice